JNJ Form 4: EVP Jennifer Taubert Exercises 56,471 Options, Sells at $177.81

Q: What did Jennifer Taubert report on Form 4 for JNJ?

The Form 4 reports the exercise of 56,471 employee stock options at $101.87 per share on 09/04/2025 and the sale of 56,471 common shares the same day at a weighted average price of $177.806 per share.

Q: How many shares did Taubert own after the reported transactions?

The filing shows beneficial ownership figures of 234,484 shares after the acquisition line and 178,013 shares after the sale line.

Q: At what prices were the transactions executed?

Options were exercised at an exercise price of $101.87 per share; the sale was executed in multiple trades at prices ranging from $177.715 to $177.89 , reported as a weighted average of $177.806 .

[Form 4] Johnson & Johnson Insider Trading Activity

Filing Impact

(High)

Filing Sentiment

(Very Positive)

Form Type

Rhea-AI Filing Summary

Jennifer L. Taubert, Executive Vice President, Worldwide Chairman - Innovative Medicine at Johnson & Johnson (JNJ), reported option exercise and an immediate sale on 09/04/2025. She exercised 56,471 employee stock options with an exercise price of $101.87 per share, producing 56,471 common shares. Those same 56,471 shares were sold the same day in multiple trades at a weighted average sale price of $177.806 per share. The Form 4 shows beneficial ownership figures of 234,484 shares following the acquisition line and 178,013 shares following the sale line. The filing is signed by an attorney-in-fact on 09/05/2025.

Insights

TL;DR: Insider exercised options and sold the same shares, realizing the spread between $101.87 and $177.806 per share.

The transaction is a routine Section 16 filing documenting the exercise of 56,471 options at $101.87 and an immediate sale of those shares at a weighted average of $177.806. This converts equity compensation into cash for the reporting person and increases public float by the exercised shares that were sold. The filing provides exact volumes and prices, with no additional commentary on intent or planned future trades.

TL;DR: This is a standard disclosure of option exercise and subsequent sale, properly reported under Section 16.

The Form 4 lists the reporting person as an officer and shows both the exercise and sale occurred on the same date, with complete price and volume details and an attorney-in-fact signature. From a governance perspective, the filing meets disclosure requirements; it does not include any amendment or indication of reliance on a Rule 10b5-1 plan within the form text provided.

09/05/2025 - 06:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taubert Jennifer L

(Last)

(First)

(Middle)

ONE JOHNSON & JOHNSON PLAZA

(Street)

NEW BRUNSWICK

08933

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
JOHNSON & JOHNSON [ JNJ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, WWC. Innovative Medicine

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/04/2025		M		56,471	A	$101.87	234,484.001	D
Common Stock	09/04/2025		S		56,471	D	$177.806⁽¹⁾	178,013.001	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Options (Right to Buy)	$101.87	09/04/2025		M			56,471	02/09/2019⁽²⁾	02/08/2026	Common Stock	56,471	$101.87	0	D

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $177.715 to $177.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

2. Vested and exercisable one day after the third anniversary of the date of the grant.

Remarks:

	/s/ Laura H. McFalls, as attorney-in-fact for Jennifer Taubert	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Jennifer Taubert report on Form 4 for JNJ?

The Form 4 reports the exercise of 56,471 employee stock options at $101.87 per share on 09/04/2025 and the sale of 56,471 common shares the same day at a weighted average price of $177.806 per share.

How many shares did Taubert own after the reported transactions?

The filing shows beneficial ownership figures of 234,484 shares after the acquisition line and 178,013 shares after the sale line.

At what prices were the transactions executed?

Options were exercised at an exercise price of $101.87 per share; the sale was executed in multiple trades at prices ranging from $177.715 to $177.89, reported as a weighted average of $177.806.

When was the Form 4 signed and filed?

The signature block shows the form was signed by an attorney-in-fact on 09/05/2025.

Does the Form 4 state whether the sale used a 10b5-1 plan?

The provided Form 4 content does not indicate that the transaction was executed pursuant to a Rule 10b5-1 trading plan.

AG真人官方

[Form 4] Johnson & Johnson Insider Trading Activity

Insights

FAQ

What did Jennifer Taubert report on Form 4 for JNJ?

How many shares did Taubert own after the reported transactions?

At what prices were the transactions executed?

When was the Form 4 signed and filed?

Does the Form 4 state whether the sale used a 10b5-1 plan?

NYSE:JNJ

JNJ Rankings

JNJ Latest News

JNJ Latest SEC Filings

JNJ Stock Data

AG真人官方

Trending News

[Form 4] Johnson & Johnson Insider Trading Activity

Insights

Financial Analyst neutral

Corporate Governance Expert neutral

FAQ

What did Jennifer Taubert report on Form 4 for JNJ?

How many shares did Taubert own after the reported transactions?

At what prices were the transactions executed?

When was the Form 4 signed and filed?

Does the Form 4 state whether the sale used a 10b5-1 plan?

NYSE:JNJ

JNJ Rankings

JNJ Latest News

JNJ Latest SEC Filings

JNJ Stock Data